GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Total Stockholders Equity

Allurion Technologies (Allurion Technologies) Total Stockholders Equity : $-66.16 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Total Stockholders Equity?

Allurion Technologies's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-66.16 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Allurion Technologies's Book Value per Share for the quarter that ended in Mar. 2024 was $-1.38. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Allurion Technologies's Debt-to-Equity for the quarter that ended in Mar. 2024 was -0.63.


Allurion Technologies Total Stockholders Equity Historical Data

The historical data trend for Allurion Technologies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies Total Stockholders Equity Chart

Allurion Technologies Annual Data
Trend Dec21 Dec22 Dec23
Total Stockholders Equity
-34.29 -32.31 -70.49

Allurion Technologies Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only -88.78 -110.34 -52.76 -70.49 -66.16

Allurion Technologies  (NYSE:ALUR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Allurion Technologies's Book Value per Share for the quarter that ended in Mar. 2024 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Allurion Technologies's Debt-to-Equity for the quarter that ended in Mar. 2024 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allurion Technologies Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Allurion Technologies (Allurion Technologies) Business Description

Traded in Other Exchanges
N/A
Address
11 Huron Drive, Natick, MA, USA, 01760
Website
Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Executives
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta director, 10 percent owner 307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth officer: Chief Financial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin director C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson director 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon officer: Chief Commercial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur director, officer: Chief Executive Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani officer: Chief Medical Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760